Tissue and plasma retinol and retinyl ester levels were determined by HPLC protocols described previously (58). Retinol and individual retinyl esters (retinyl palmitate, oleate, linoleate, and stearate) were detected at 325 nm and identified by comparing the retention times and spectral data of experimental compounds with those of authentic standards. Concentrations of retinol and retinyl esters in the tissues were quantitated by comparing integrated peak areas for each retinoid against those of known amounts of purified standards. Loss during extraction was accounted for by adjusting for the recovery of internal standard retinyl acetate added immediately after homogenization of the samples.
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LC/MS/MS analyses of tissue concentrations of endocannabinoids and endocannabinoidlike substances
Intestinal mucosa levels of endocannabinoids (2-AG and AEA) and the endocannabinoid-like NAEs (including MEA, PEA, OEA, LEA, and SEA) and 2-MAGs (2-OG, 2-LG, and 2-PG) were determined by LC/MS/MS according to protocols we described in detail earlier (59) .
MAG binding to purified mouse RBP2
To allow for the purification of mouse RBP2, the synthetic cDNA sequence of mouse RBP2 (GI:255759938, NP_033060.3) was purchased from Origene Technologies and subcloned into pET3b vector (Novagen) using the following primers: forward -GCAGATCATATGACGAAGGACCAAAATGGAACC and reverse -CGTCTACTCGAGCTTCTTTTTGAACACTTGTCGG. The protein tagged with a C-terminal six histidine residues was expressed in the BL21 (DE3) E. coli strain (New England Biolabs).
The bacteria were incubated at 37 °C in the presence of 50 µM kanamycin to OD600 = 0.6 -0.8 prior to addition of isopropyl β-D-1 thiogalactopyranoside (Roche) to a final concentration of 0.5 mM. After an additional 4 h of incubation, cells were harvested by centrifugation (6,000 × g, 15 min, 4 °C). Bacteria were disrupted by osmotic shock and the lysate was centrifuged at 36,000 × g for 30 min at 4 °C. The supernatant was collected. Its buffer composition was adjusted to 50 mM Tris-HCl, pH 8.0, 250 mM NaCl (loading buffer) prior to loading onto a column filled with 5 mL of Ni-NTA agarose resin (Qiagen). The column was washed with 100 mL of loading buffer containing 5 mM imidazole and bound proteins were eluted by increasing imidazole concentration to 250 mM. Eluted fractions were examined by SDS-PAGE, combined and concentrated to 5 mL in an Amicon Ultra-4 centrifugal filter, cutoff 10,000 Da (Millipore). For the final step of purification, the protein solution was diluted 40 fold to a final volume of 200 mL with 10 mM Tris-HCl buffer, pH 8.0 and loaded onto a 5 mL HiTrap Q HP ion exchanger column (GE Healthcare). RBP2 was eluted with a gradient of NaCl (0 -0.5 M) over 30 min at a flow rate 1.0 mL/min. Collected fractions were re-examined by SDS-PAGE and those containing purified RBP2 were pooled together. The protein was concentrated to 3 mg/mL and 0.2 mL aliquots were stored at -80 °C.
To obtain holo-RBP2, 3 mg of purified apo-protein was incubated for 20 min on ice in 10 mM Tris-HCl, pH 8.0, 10% glycerol (v/v) with an approximate 2 molar excess of all-trans-retinol (Toronto Research Company) delivered in DMSO (2%, v/v). To remove unbound retinoid, the protein solution was diluted 10 fold with 10 mM Tris-HCl, pH 8.0, centrifuged to remove precipitates (36,000 x g, 20 min, 4 °C), and loaded onto a 5 mL HiTrap Q HP column. holo-RBP2 was eluted from the column as described above. The efficiency of holo-RBP2 formation was examined spectrophotometrically by recording the UV/Vis spectrum. The complex of RBP2 with all-trans-retinol revealed characteristic two absorbance maxima at 280 and 348 nm with ratio between them approximately 1.3.
To assess the ability of MAGs and NAEs to replace retinol from its binding site in RBP2, 500 g of holo-RBP2 in 0.5 mL (80 M) was incubated with a 2 molar excess of tested compound delivered in ethanol in 20 mM Tris/HCl, pH 8.0, 200 mM NaCl, 10% glycerol at room temperature for 15 min. The sample was then diluted with 10 mM Tris/HCl, pH 8.0 to the final volume of 5 mL, loaded onto HiTrap Q HP column, and eluted as described above. The elution profiles were monitored at both 280 and 325 nm in order to concurrently record signals from protein and all-trans-retinol. After incubation of apo-or holo-RBP2 with 2-AG and following re-purification as described above, the protein fractions were collected, pooled together, and concentrated to 0.25 mL in an Amicon Ultra-4 centrifugal filter, cutoff 10,000 Da. To precipitate the protein to extract 2-AG, 0.5 mL of ethanol was added and the sample was centrifuged at 26,000 x g for 5 min. The resulting supernatant was dried down under a stream of nitrogen and the residual pellet was resuspended in 0.3 mL acetonitrile. One hundred L of the sample was injected onto ZORBAX XDB-C18 column, 5 m, 4.5 x 150 mm (Agilent Technologies) equilibrated with 50% water in acetonitrile (v/v). 2-AG was separated in a gradient of acetonitrile in water (50% to 100%) developed over 15 min at a flow rate 1 mL/min. The eluent was directed into an LXQ ion trap mass spectrometer (Thermo Scientific) via an atmospheric pressure chemical ionization source working in the positive mode. The mass spectrometer operation parameters were optimized using synthetic 2-AG.
Fluorescence binding assays
The binding affinities of 2-AG, 2-OG, 2-LG, 1-AG and AEA for mouse RBP2 was evaluated by monitoring the increase of protein fluorescence and the correlated decrease of fluorescence resonance energy transfer (FRET) between the protein scaffold and the retinoid (63). Both effects can be attributed to replacement of all-trans-retinol in the binding site by tested ligands (63). All measurements were performed on a PerkinElmer Life Sciences LS55 model fluorometer. The excitation wavelength was set at 285 nm, whereas emission spectra were recorded between 300 and 560 nm with 10 nm bandwidths for excitation and emission. Titrations were carried out at 25 °C in 67 mM phosphate buffered saline buffer, pH 7.4, containing 5% glycerol (v/v) by adding an increasing amount of MAGs (0 -300 nM) or NAE (0 -3000 nM).
The ligands were delivered in ethanol, in which final concentrations did not exceed 0.4% of the sample's total volume. All fluorescence spectra were background corrected. Apparent Kd values were calculated by fitting intensities of protein fluorescence at maximum emission (378 nm) or the intensity of retinoid fluorescence at 478 nm that resulted from FRET to the saturation single ligand-binding models available in the SigmaPlot 11 software package (Systat Software).
Crystallization of human RBP2, X-ray diffraction data collection and processing
The cDNA of human RBP2 (NP_004155.2) was purchased from Origene Technologies and amplified by PCR using the following primers: forward -GCAGATCATATGACAAGGGACCAGAATGGAACC and reverse -CGTCTACTCGAGTCCCGGGGATCCACGCGGAACCAGTTTCTTTTTGAACACTTGACG G. Thus, the C-terminal sequence was modified to introduce thrombin cutting site that allowed for removal of His-tag from the purified protein. The initial steps of expression and purification were analogical to those described above for the mouse RBP2. After affinity chromatography on the Ni-NTA agarose resin, the protein was loaded onto gel filtration column Superdex 200 (GE Healthcare) equilibrated with 10 mM Tris/HCl buffer, pH 8.0. Fractions containing RBP2 were pooled and incubated with thrombin (USB Affymetrix) for 4 h at room temperature. After adjusting ionic strength of the protein solution by adding NaCl to the final concentration of 300 mM, digested RBP2 was re-loaded onto a 5 mL Ni-NTA agarose column. Unbound fraction that contained digested protein was collected, diluted to 20 times with 10 mM Tris/HCl buffer, pH 8.0 buffer and loaded onto HiTrap Q HP ion exchanger column for the final step of purification.
RBP2 was eluted with a gradient of NaCl (0 -0.5 M) over 30 min at a flow rate 1.0 mL/min.
Purity of the collected protein fractions were checked by SDS-PAGE. The protein was concentrated to 9 mg/mL and 0.2 mL aliquots were stored at -80°C. To obtain crystals of human RBP2 in complex with non-retinoid lipids, the apo protein at 9 mg/mL concentration was preincubated with 50 μM of the ligand in 10 mM Tris-HCl buffer, pH 8.0, 150 mM NaCl for 20 minutes on ice. One μL of this protein sample was mixed in 1:1 ratio with a crystallization solution. Crystals of RBP2 were obtained with the siting drop vapor diffusion method at room temperature in variety of crystallization conditions that included 0.1 M Tris-HCl, pH between 7.5 and 8.5 and PEG 3350 at the concentration range 22 -28%.
Crystals were harvested, cryo-protected in mother liquor supplemented with 10% glycerol plus 10% PEG 2000 (v/v) and flash cooled in liquid nitrogen. X-ray diffraction data were collected at the APS NE-CAT 24-ID-C or 24-ID-E beamlines using the continuous vector scanning option to maximize diffraction resolution and distribute the dose over the entire crystal. Data from single crystals were integrated and scaled with XDS (64). The structure of RBP2-2AG was solved by molecular replacement with an automated molecular replacement pipeline -Balbes CCP4 (65).
Initial model was manually adjusted in COOT (66) and refined with PHENIX (67), using a riding hydrogen model, individual anisotropic temperature factors, and occupancy refinement for alternative conformers and waters. Geometry of the refined model was verified with the MolProbity server (68). The data collection and refinement statistics are summarized in Supplementary Table 1 . Visualization of the macromolecules and figure preparation were performed in the CHIMERA software package version 1.10.1 (69).
Plasma and tissue triglyceride and FFA measurements
Blood was collected from mice for measurement of plasma TGs and FFAs. TGs from plasma and tissue aliquots were measured enzymatically using Infinity kits (ThermoFisher Scientific Inc.)
according to the manufacturer's instructions. FFAs were measured using a NEFA kit (Wako Pure Chemical Industries) according to the manufacturer's instructions. For measurement of tissue lipids, mice underwent whole body perfusion with ice cold PBS and the dissected tissues were then homogenized at 4 o C in PBS. Lipids were extracted from approximately 50 mg tissue in 6 volumes of 2:1 (v/v) chloroform/methanol. The chloroform extractable lipids were dried under a gentle stream of N2, subsequently solubilized in water containing 2% (v/v) Triton X-100 and aliquots taken for assay.
Hepatic VLDL production
Mice were fasted for 4-5 h and then injected ip with the total lipase inhibitor P-407, at 1 mg/g body weight (24). Retro-orbital blood samples were taken at immediately prior to injection (0 h) and after injection (2 and 4 h) for plasma TG measurement as described above.
Determination of body composition, adipocyte size and metabolic parameters
Body composition was determined by Minispec mq10 NMR analyzer (Bruker Optics, Woodlands, TX) or dual energy X-ray absorptiometry (DEXA) densitometry (PIXImus2, Fitchburg, WI) following the manufacturer's instructions. Briefly, for Minispec operation, conscious mice are placed inside the tube animal holder and body composition measurement is done in a 50-60 seconds. For DEXA, sedated mouse is placed on the animal holder below the beam area and measurement is completed within 2-3 minutes. Afterwards, the mice were placed back in their home cages and used for experiments.
Adipocyte surface area was quantified in H&E stained adipose tissue sections using an Olympus FSX100 microscope and software as we have earlier reported (11). The mean adipocyte surface area was calculated from a minimum of 100 adipocytes present in 5-8 randomly chosen fields for three mice per group.
Metabolic parameters were determined using the automated open circuit indirect calorimetry system Comprehensive Laboratory Animal Monitoring System Oxymax (CLAMS Oxymax;
Columbus Instruments, Columbus, OH) housed in an environmentally-controlled cabinet (70).
The calorimetry system simultaneously measures O2 consumption (VO2), CO2 production (VCO2), respiratory exchange rate (RER), heat or energy expenditure, activity, and food consumption.
Studies of glucose homeostasis and blood hormone levels
Blood was collected from conscious animals by submandibular bleed into 1.5 mL Eppendorf tubes containing EDTA. Cells were removed by centrifugation at 11,200 rcf for 20 min at 4 ºC.
Plasma was carefully decanted and frozen at −80 °C until analysis. At the time of the blood draw, capillary (tail) blood glucose concentrations were measured using the FreeStyle Flash Blood glucose monitoring system from Abbott (Alameda, CA). For the fasted state, blood was drawn at 1 p.m., 12 h after food had been removed. For the fed state, blood was drawn at midnight, 5 h after the start of refeeding during the dark cycle. As a glucose challenge, mice in the fasted state received an ip glucose dose of 1 g glucose/kg body weight and blood glucose levels were measured from the tail vein; submandibular blood was obtained at multiple time intervals for determination of insulin. Mice used for glucose (ipGTT) and insulin (ipITT) tolerance tests were fasted overnight. For ipGTTs, mice received 1 g glucose/kg body weight.
For ipITTs, mice received 0.7 U human insulin/kg body weight.
Commercially available ELISA kits were employed for measurement of plasma insulin, GIP, GLP-1, and CCK8 levels. Blood insulin was assessed using an ALPCO mouse ultrasensitive ELISA kit # 80-INSMSU-E01. GIP and GLP-1 were measured using ELISA kits from Crystal Chem, item # 81517 and item # 90080 respectively. CCK8 was measured using an ELISA kit from Cloud-Clone Corp kit # CEB044Mu.
RNA isolation and quantitative Real Time-PCR (qRT-PCR)
Total RNA was isolated from tissues using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA samples were DNase I-digested employing the RNeasy mini kit (Qiagen) to remove residual genomic DNA and subsequently quantified using a NanoDrop spectrophotometer. For cDNA synthesis, 1 µg of total RNA was reverse-transcribed using the High Capacity Reverse Transcription Kit (Applied Biosystems). cDNA synthesis was carried out for 10 min at 20 o C and 120 min at 37 o C. The reaction was stopped by incubation at 85 o C for 5 min using a thermal cycler (Eppendorf). qRT-PCR was performed in a total volume of 25 µl, 
